D/C/F/TAF is a once-daily darunavir-based single-tablet regimen, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg.
Genotypic testing should guide the use of D/C/F/TAF.
Results from the AMBER study demonstrated that a high proportion of antiretroviral treatment -naïve adults with HIV-1 (85%, 308/362) maintained virologic suppression (viral load
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results